Cedars-Sinai Heart Institute, Los Angeles, CA.
Stanford University, Stanford, CA.
Am J Transplant. 2017 Oct;17(10):2559-2566. doi: 10.1111/ajt.14354. Epub 2017 Jun 13.
Cardiac transplantation remains the only definitive treatment for end-stage heart failure. Transplantation rates are limited by a shortage of donor hearts. This shortage is magnified because many hearts are discarded because of strict selection criteria and concern for regulatory reprimand for less-than-optimal posttransplant outcomes. There is no standardized approach to donor selection despite proposals to liberalize acceptance criteria. A donor heart selection conference was organized to facilitate discussion and generate ideas for future research. The event was attended by 66 participants from 41 centers with considerable experience in cardiac donor selection. There were state-of-the-art presentations on donor selection, with subsequent breakout sessions on standardizing the process and increasing utilization of donor hearts. Participants debated misconceptions and established agreement on donor and recipient risk factors for donor selection and identified the components necessary for a future donor risk score. Ideas for future initiatives include modification of regulatory practices to consider extended criteria donors when evaluating outcomes and prospective studies aimed at identifying the factors leading to nonacceptance of available donor hearts. With agreement on the most important donor and recipient risk factors, it is anticipated that a consistent approach to donor selection will improve rates of heart transplantation.
心脏移植仍然是治疗终末期心力衰竭的唯一有效方法。由于供体心脏短缺,移植率受到限制。由于严格的选择标准以及对移植后结果不如理想时的监管处罚的担忧,许多心脏被丢弃,这使得短缺情况更加严重。尽管有提议放宽接受标准,但仍没有标准化的供体选择方法。组织了一次供体心脏选择会议,以促进讨论并为未来的研究提供思路。来自 41 个中心的 66 名参与者参加了此次会议,他们在心脏供体选择方面拥有丰富的经验。会上就供体选择进行了最先进的演示,随后就标准化流程和增加供体心脏的利用进行了分组讨论。与会者对误解进行了辩论,并就供体和受体选择供体的风险因素达成了一致意见,并确定了未来供体风险评分所需的组成部分。未来举措的想法包括修改监管实践,在评估结果时考虑扩展标准供体,以及旨在确定导致不可接受的可用供体心脏的因素的前瞻性研究。随着对最重要的供体和受体风险因素的一致意见,预计一致的供体选择方法将提高心脏移植的比例。